Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22416064 | 0.89 | CHRM1 (0.83) | CHRM1SMN1; SMN2LMNATHRBPOLB | |
| SCHEMBL16341817 | 0.89 | CHRM1 (1.00) | CHRM1SMN1; SMN2P2RX7LMNATHRB | |
| SCHEMBL16341842 | 0.86 | CHRM1 (0.78) | CHRM1SMN1; SMN2LMNATHRBPOLB | |
| SCHEMBL16341505 | 0.86 | CHRM1 (0.78) | CHRM1SMN1; SMN2LMNATHRBPOLB | |
| SCHEMBL2485404 | 0.86 | CHRM1 (0.93) | CHRM1SMN1; SMN2LMNA | |
| SCHEMBL16378027 | 0.85 | CHRM1 (0.76) | CHRM1SMN1; SMN2P2RX7 | |
| SCHEMBL16341587 | 0.84 | CHRM1 (0.74) | CHRM1SMN1; SMN2LMNATHRB | |
| SCHEMBL16341784 | 0.83 | CHRM1 (0.72) | CHRM1SMN1; SMN2LMNATHRB | |
| SCHEMBL16341768 | 0.83 | CHRM1 (0.72) | CHRM1SMN1; SMN2 | |
| SCHEMBL16341521 | 0.83 | CHRM1 (0.72) | CHRM1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2821401-B1 | DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-09 | — | — | EP | disclosed |
| EP-2821401-B1 | DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2821401-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | Takeda Pharmaceutical Company Limited (JP) | 2015-01-07 | — | — | EP | disclosed |
| EP-2821401-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | Takeda Pharmaceutical Company Limited (JP) | 2015-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885SMN1; SMN2 2464/4885P2RX7 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.